Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06644534Phase 2Recruiting

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

Role: lead

NCT06990984Phase 2Not Yet Recruiting

A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

Role: lead

NCT05212662Phase 2Withdrawn

Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Role: lead

All 3 trials loaded